City Research Online

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate

Lunt, S. J., Akerman, S., Hill, S. A. , Fisher, M., Wright, V. J., Reyes-Aldasoro, C. C. ORCID: 0000-0002-9466-2018, Tozer, G. M. & Kanthou, C. (2011). Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate. International Journal of Cancer, 129(8), doi: 10.1002/ijc.25848

Abstract

Vascular-targeted therapeutics are increasingly used in the clinic. However, less is known about the direct response of tumor cells to these agents. We have developed a combretastatin-A-4-phosphate (CA4P) resistant variant of SW1222 human colorectal carcinoma cells to examine the relative importance of vascular versus tumor cell targeting in the ultimate treatment response. SW1222Res cells were generated through exposure of wild-type cells (SW1222WT) to increasing CA4P concentrations in vitro. Increased resistance was confirmed through analyses of cell viability, apoptosis and multidrug-resistance (MDR) protein expression. In vivo, comparative studies examined tumor cell necrosis, apoptosis, vessel morphology and functional vascular end-points following treatment with CA4P (single 100 mg/kg dose). Tumor response to repeated CA4P dosing (50 mg/kg/day, 5 days/week for 2 weeks) was examined through growth measurement, and ultimate tumor cell survival was studied by ex vivo clonogenic assay. In vitro, SW1222Res cells showed reduced CA4P sensitivity, enhanced MDR protein expression and a reduced apoptotic index. In vivo, CA4P induced significantly lower apoptotic cell death in SW1222Res versus SW1222WT tumors indicating maintenance of resistance characteristics. However, CA4P-induced tumor necrosis was equivalent in both lines. Similarly, rapid CA4P-mediated vessel disruption and blood flow shut-down were observed in both lines. Cell surviving fraction was comparable in the two tumor types following single dose CA4P and SW1222Res tumors were at least as sensitive as SW1222WT tumors to repeated dosing. Despite tumor cell resistance to CA4P, SW1222Res response in vivo was not impaired, strongly supporting the view that vascular damage dominates the therapeutic response to this agent.

Publication Type: Article
Additional Information: Copyright © 2010 UICC. This is the peer reviewed version of the following article: Lunt, S. J., Akerman, S., Hill, S. A. , Fisher, M., Wright, V. J., Reyes-Aldasoro, C. C. , Tozer, G. M. & Kanthou, C. (2011). Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate. International Journal of Cancer, 129(8), which has been published in final form at https://doi.org/10.1002/ijc.25848. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
Publisher Keywords: combretastatin, vascular targeting, drug resistance, tumor
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Departments: School of Mathematics, Computer Science & Engineering > Computer Science
[img]
Preview
Text - Accepted Version
Download (1MB) | Preview

Export

Downloads

Downloads per month over past year

View more statistics

Actions (login required)

Admin Login Admin Login